GLP-1, incretin multi-agonist and amylin trial starts vs Autoimmune cell therapy and T-cell engager trial starts
In 2025, GLP-1, incretin multi-agonist and amylin trial starts worldwide stood at 223, against 112 for autoimmune cell therapy and T-cell engager trial starts.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
GLP-1, incretin multi-agonist and amylin trial starts and Autoimmune cell therapy and T-cell engager trial starts
Unit: count · 12 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| GLP-1, incretin multi-agonist and amylin trial starts | 2025 | Actual | 223 |
| GLP-1, incretin multi-agonist and amylin trial starts | 2024 | Actual | 191 |
| GLP-1, incretin multi-agonist and amylin trial starts | 2023 | Actual | 142 |
| GLP-1, incretin multi-agonist and amylin trial starts | 2022 | Actual | 104 |
| GLP-1, incretin multi-agonist and amylin trial starts | 2021 | Actual | 101 |
| GLP-1, incretin multi-agonist and amylin trial starts | 2020 | Actual | 66 |
| Autoimmune cell therapy and T-cell engager trial starts | 2025 | Actual | 112 |
| Autoimmune cell therapy and T-cell engager trial starts | 2024 | Actual | 91 |
| Autoimmune cell therapy and T-cell engager trial starts | 2023 | Actual | 17 |
| Autoimmune cell therapy and T-cell engager trial starts | 2022 | Actual | 6 |
| Autoimmune cell therapy and T-cell engager trial starts | 2021 | Actual | 7 |
| Autoimmune cell therapy and T-cell engager trial starts | 2020 | Actual | 2 |
Shared periods
Side by side
6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | GLP-1, incretin multi-agonist and amylin trial starts | Autoimmune cell therapy and T-cell engager trial starts |
|---|---|---|
| 2020 | 66 ClinicalTrials.gov | 2 ClinicalTrials.gov |
| 2021 | 101 ClinicalTrials.gov | 7 ClinicalTrials.gov |
| 2022 | 104 ClinicalTrials.gov | 6 ClinicalTrials.gov |
| 2023 | 142 ClinicalTrials.gov | 17 ClinicalTrials.gov |
| 2024 | 191 ClinicalTrials.gov | 91 ClinicalTrials.gov |
| 2025 | 223 ClinicalTrials.gov | 112 ClinicalTrials.gov |
Provenance
Where these numbers come from
GLP-1, incretin multi-agonist and amylin trial starts
Count of interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Autoimmune cell therapy and T-cell engager trial starts
Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring